[Central stimulants in adults with AD/HD. Do they help?]

Area of Science:

• Psychiatry and Behavioral Sciences
• Clinical Pharmacology

Context:

• Review of five controlled studies on methylphenidate for adult attention deficit/hyperactivity disorder (AD/HD).
• Analysis of study designs, diagnostic criteria, and patient selection in existing research.
• Assessment of methylphenidate's short-term and long-term efficacy in adults.

Purpose:

• To critically evaluate the scientific evidence supporting the use of methylphenidate in adults diagnosed with AD/HD.
• To identify limitations in current research methodologies and their impact on observed outcomes.
• To determine if methylphenidate demonstrates a clear therapeutic benefit for adult AD/HD.

Summary:

• Most reviewed studies had methodological flaws, including questionable blinding and inappropriate diagnostic criteria.
• Only one study with acceptable design found no significant difference between methylphenidate and placebo.
• Long-term follow-up revealed that only a small fraction of initially improved patients continued methylphenidate treatment.

Impact:

• Current evidence does not support the efficacy of methylphenidate for treating AD/HD in adults.
• Findings suggest that the long-term benefits of methylphenidate in this population are questionable.
• Further high-quality research is needed to clarify the role of methylphenidate in adult AD/HD management.